Clinical and Genomic Characteristics of Patients with HR+, HER2- Metastatic Breast Cancer Following Progression on a CDK4 and 6 Inhibitor.

Xi Rao Yongmei Chen Julie Beyrer Emily Nash Smyth Claudia Morato Guimaraes Lacey M Litchfield Lee Bowman Garreth W Lawrence Amit Aggarwal Fabrice Andre

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Distinct mechanisms potentially associated with resistance to CDK4 & 6i +/- ET, including alterations in ESR1 and amplification of chr12q15 and CDK4 copy number gain, were identified.

Keyphrases

copy number
metastatic breast cancer
cell cycle
mitochondrial dna
genome wide
dna methylation
cell proliferation
gene expression
estrogen receptor